Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147653 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy
A Phase 2 study, sponsored by Joanne Kurtzberg, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01147653: Completed Phase 2 study, sponsored by Joanne Kurtzberg, MD.
NCT01147653 is a Phase 2 study that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01147653, a Phase 2 study, has completed, sponsored by Joanne Kurtzberg, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of a single intravenous infusion of autologous umbilical cord blood (UCB) for the treatment of pediatric patients with spastic cerebral palsy.
Primary Outcome
Change in Gross Motor Function Measure 66 (GMFM-66) Score from Baseline to Year 1. The GMFM-66 is a clinical tool used to evaluate gross motor function in children with cerebral palsy and is scored using a propriety software program called the Gross Motor Ability Estimator (GMAE) that produces an interval level continuous score ranging from 0 to 100. Higher scores indicate better motor function. A negative change in GMFM-66 score indicates a reduction in motor function, a positive change indicat
Interventions
- OTHER Placebo
- BIOLOGICAL Autologous UCB Reinfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
What the finished NCT01147653 record still lists
NCT01147653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01147653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01147653 about?
NCT01147653 is a clinical study titled "A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy". The purpose of this study is to determine the efficacy of a single intravenous infusion of autologous umbilical cord blood (UCB) for the treatment of pediatric patients with spastic cerebral palsy.
What is the current status of trial NCT01147653?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2010-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01147653?
The interventions under investigation include: Placebo (OTHER), Autologous UCB Reinfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT01147653?
This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01147653's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia